Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07629778 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv2 Show 6 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 11, 2026 to May 26, 2026
    • Interventions: HL-300 (Drug), Placebo (Drug) to HL-300 (Drug), HL-300 (Drug), HL-300 (Drug), Placebo (Drug)
    • Secondary endpoints revised (11)
    • Study description expanded, about 3 words
    • Study title shortened, about 5 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.
Trial Details
NCT Number NCT07629778
Lead Sponsor Hangzhou Highlightll Pharmaceutical Co., Ltd
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic
Enrollment 156 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov